Loading...
OTC Markets
Totals
Securities
12,313
Dollar Vol
$2.5B
Share Vol
3.3B
Trades
366,887

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

EMOR
Healixa Inc.

Common Stock

0.0138

-0.0012

-8.00%

0.009 / 0.015 (1 x 1)

Real-Time Best Bid & Ask: 05:00pm 07/15/2025
Delayed (15 Min) Trade Data: 01:57pm 07/15/2025
OTC Disclosure & News Service

New York, NY, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Emerald Organic Products, Inc. (OTC:EMOR) (“Emerald” or the “Company”) is pleased to announce that it has formally entered into an exclusive licensing agreement for the use of OraPatch™, a patented oral delivery method for various substances including caffeine and cannabidiol (“CBD”) from PetVivo Holdings, Inc. (OTC:PETV) (“PetVivo”).

0_medium_Pura-Vida-Vitamins.png


The patented oral adhesion technology, OraPatch™, is a slowly degradable protein wafer-disc that attaches to and assimilates with the mouth's inner lining. PetVivo is the holder of patents for this unique and cutting-edge method for nutraceutical and supplement delivery. 

The fully dissolving wafer-like invention sticks strongly and comfortably the roof of the mouth, cheeks, or gums. This delivery method provides both a rapid release and greater bioavailability when compared to ingestion. Furthermore, the OraPatch product only uses materials deemed to be Generally Recognized as Safe (“GRAS”) by the United States Food and Drug Administration (the “FDA”).

“The potential introduction of this technology to our line of products can change the entire dynamics and approach to both our vitamin and nutraceutical markets, especially for our flagship PURA CBD products” said Emerald Organic Products, Inc. CEO, Ian Parker. 

John Lai, President of PetVivo said, “We were waiting for the right consumer branding team to license this extraordinary, cutting edge technology to. Clearly, the management pedigree of Emerald is best-in-class in the emerging cannabinoid market.” Lai continued, “In the right hands, this product has the potential to revolutionize the vitamin and CBD market place and we are confident we found the right team partner in Emerald.”

Using safe materials, the efficiency afforded by this new patented delivery technology may allow for enhanced bioavailability and efficacy while employing lower and more exact product doses, thereby reducing potential stomach irritations and risks of toxicity.

“There is no delivery system like it in the market. The potential use of this brand new delivery method breakthrough, known as the “OraPatch” can create a paradigm shift in the way CBD and other cannabinoids are delivered to and ingested by consumers,” added Parker. “OraPatch has applications that will uniquely distinguish Emerald as a category leader in the CBD market. No other brand will be able to match our industry recognized top quality product combined with our newly acquired patented delivery system that has applications to so many highly profitable market segments”

About Emerald Organic Products, Inc.

Headquartered in Long Island, NY, Emerald Organic Products Inc. (OTC:EMOR), through its flagship brand, Pura Vida Vitamins, formulates and manufactures health and wellness products including hemp-derived CBD-infused gummies, tinctures, topical creams, and other vitamin and health formulations. Committed to customer satisfaction, each and every Pura Vida Vitamins’ product is priced to provide industry-leading value and comes with a purity guarantee that offers peace of mind and product transparency.

About PetVivo Holdings Inc.

PetVivo Holdings Inc. (OTC:PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for animal and pet therapeutics as well as for human applications.  PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time-efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes, and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.   

Safe Harbor Statement: Statements in this news release may be "forward-looking statements". Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and neither PetVivo Holdings Inc., Pura Vida Health, LLC nor Emerald Organic Products, Inc. undertakes any obligation to update any forward-looking statements to reflect events or circumstances after the date of this news release.

John Lee
Emerald Organic Products Inc.
1-855-540-0354
jlee@puravidavitamins.com

John Lai
PetVivo Holdings, Inc.
jlai@petvivo.co
The Pink Limited Market is for broker-dealers to publicly quote securities with limited to no issuer involvement. Pink Limited companies do not certify their compliance with established reporting standards, have limited availability of disclosure or financial information and may not support their U.S. market. These securities are identified with a yield sign to warn investors to proceed with caution.
Limited Information Icon
Pink Limited Information
The Company Profile data was verified by the issuer within the previous 6 months.
The company’s transfer agent has verified its outstanding shares directly to OTC Markets.
Daily Advancers
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.